A Director at Opexa Therapeutics (NASDAQ: OPXA) is Selling Shares

By Carrie Williams

Today, a Director at Opexa Therapeutics (NASDAQ: OPXA), Timothy Barabe, sold shares of OPXA for $8,202.

This is Barabe’s first Sell trade following 10 Buy transactions.

The company has a one year high of $5.10 and a one year low of $0.50. Currently, Opexa Therapeutics has an average volume of 23.2K.

Based on 3 analyst ratings, the analyst consensus is Hold with an average price target of $1.00, reflecting a 47.0% upside.

The insider sentiment on Opexa Therapeutics has been negative according to 16 insider trades in the past three months. This sentiment is equal to the average sentiment of company insiders in this sector.

Opexa Therapeutics, Inc. engages as a biopharmaceutical company which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. The company was founded in March 1991 and is headquartered in The Woodlands, TX.